US Phase II study for GrassMATAMPL initiated
GMM is developed from Allergy Therapeutics' successfully marketed Pollinex Quattro Grass product, which has been available in Europe for a number of years treating circa 250,000 patients1, and is designed to provide a uniquely ultra-short course of injections to prevent seasonal grass allergy. Grass allergy occurs in up to 50% of the US population2 of those suffering from seasonal allergic rhinitis/conjunctivitis, and is often poorly controlled by anti-leukotrienes and nasal corticosteroids.
Manuel Llobet, CEO of Allergy Therapeutics, said: "The US clinical development programme for our ultra-short course, aluminium-free allergy vaccine for grass remains on track. We continue to expect to file for US approval at the end of 2018. The US allergy immunotherapy market has historically been serviced by subcutaneous rather than sublingual compounded vaccines. We are therefore confident that the availability of an FDA-approved subcutaneous vaccine, which we are striving to achieve, will facilitate a fast penetration and broad acceptance of the product among the prescriber base."
Комментарии